Forbes August 13, 2021
Twenty years ago, the mapping of the human genome promised new opportunities for genomic or genetic tests to predict, prevent and even treat disease, tailored to specific patient sub-populations. For example, tests for breast cancer, such as Oncotype Dx, can analyze disease risk, and guide screening and treatment modalities for patients.
Presently, there are thousands of genetic and genomic tests on the market for more than 10,000 conditions. In addition, hundreds of drugs include genetic markers in their labels to direct prescribing of treatments, and at least one-third of drugs in the pipeline include genetic markers.*
Yet, the perennial question is, will these diagnostic tests be paid for, and at what price? The American Clinical Laboratory Association and the Personalized...
Today's Sponsors
Today's Sponsor